(Q39625657)

English

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.

scientific article published on 30 November 2010

Statements

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. (English)
Juyong Yoon
Kyoung-Hwa Koo
Kang-Yell Choi
30 November 2010
445-453

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit